Stryker stock falls 7.7% on supply-chain disruptions affecting medical-device maker

Stryker stock declined 7.7% on supply-chain concerns. The affected products, suppliers, geographies, and quantified impact on shipments, revenue or margins are not yet known.

Stryker's most recently cited fiscal-year figures provide the operating backdrop: revenue was $25.1B, up 11.2% year over year, with a 64.0% gross margin, a 12.9% net margin and diluted EPS of $8.40. Those are annual figures for the year ended December 31, 2025, rather than a measure of the current disruption.

The direct mechanism is operational: constrained components or logistics could delay product deliveries and raise costs, affecting the revenue line first and potentially gross margin if expedited sourcing or production is required. No specific Stryker division, supplier or contract has been identified.

The key uncertainty is material. Whether the problem is temporary, industry-wide or specific to Stryker remains unknown, and no revised forecast or management response has been made. The next decisive evidence would be a company update or the next quarterly results, including any change to shipment trends, revenue guidance or margin expectations.